ArticlePloS one2015
Secondary primary malignancy risk among patients with esophageal cancer in Taiwan: a nationwide population-based study.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Current status of esophageal endoscopy including the evaluation of smoking and alcohol consumption in Japan: an analysis based on the Japan endoscopy database.Esophagus : official journal of the Japan Esophageal Society · 2019Trial
- Successful robot-assisted minimally invasive surgery for scirrhous gastric conduit cancer after esophagectomy: A case report.Oncology letters · 2025Article
- Concurrent esophageal squamous cell carcinoma with gastric mucosa-associated lymphoid tissue lymphoma: a case report.Frontiers in oncology · 2025Article
- Surveillance for metachronous cancers after endoscopic resection of esophageal squamous cell carcinoma.Clinical endoscopy · 2024Review
- Association of Definitive Radiotherapy for Esophageal Cancer and the Incidence of Secondary Head and Neck Cancers: A SEER Population-Based Study.World journal of oncology · 2024Article
- Impact of radiotherapy on second primary lung cancer incidence and survival in esophageal cancer survivors.Scientific reports · 2024Article
- High incidence of lung cancer death after curative endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma.Cancer medicine · 2024Article
- Similar survival after endoscopic submucosal dissection and esophagectomy in early esophageal cancer and synchronous or metachronous head and neck cancer.Journal of cardiothoracic surgery · 2024Article
- Risk of Second Primary Cancer Among Patients with Cardio-Esophageal Cancer in Finland: A Nationwide Population-Based Study.Clinical epidemiology · 2024Article
- Risk of second cancer in esophageal squamous cell carcinoma and adenocarcinoma survivors: a population-based analysis in SEER dataset.Translational gastroenterology and hepatology · 2023Article
- Article
- Second primary malignancies in patients with clinical T1bN0 esophageal squamous cell carcinoma after definitive therapies: supplementary analysis of the JCOG trial: JCOG0502.Journal of gastroenterology · 2022Article
- Clinicopathological features and prognosis of gastric tube cancer after esophagectomy for esophageal cancer: a nationwide study in Japan.Esophagus : official journal of the Japan Esophageal Society · 2022Article
- Case report: Quadruple primary malignant neoplasms including esophageal, ureteral, and lung in an elderly male.Open life sciences · 2022Article
- Increased risk of second primary tumours in patients with oesophageal squamous cell carcinoma: a nationwide study in a Western population.United European gastroenterology journal · 2021Article
- Excessive risk of second-cancer incidence and cancer mortality in patients with esophageal cancer.Journal of gastroenterology · 2021Article
- Second Primary Malignancies in Patients with Pancreatic Neuroendocrine Neoplasms: A Population-Based Study on Occurrence, Risk Factors, and Prognosis.Journal of oncology · 2021Article
- Risk of second primary malignancies after definitive treatment for esophageal cancer: A competing risk analysis.Cancer medicine · 2020Article
- Incidence of Second Malignancy in Patients with Papillary Thyroid Cancer from Surveillance, Epidemiology, and End Results 13 Dataset.Journal of thyroid research · 2018Article
- Survival impact of locoregional metachronous malignancy in survival of lung cancer patients who received curative treatment.Journal of thoracic disease · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundTo evaluate the risk and sites of metachronous secondary primary malignancies (SPMs) among patients with esophageal cancer.
methodsNewly diagnosed esophageal cancer patients between 1997 and 2011 were recruited. To avoid surveillance bias, SPMs that developed within one year were excluded. Standardized incidence ratios (SIRs) of metachronous SPMs in these patients were calculated by comparing to the cancer incidence in the general population. Risk factors for SPM development, included age, sex, comorbidities and cancer-related treatments, were estimated by Cox proportional hazards models.
resultsDuring the 15-year study period, 870 SPMs developed among 18,026 esophageal cancer patients, with a follow-up of 27,056 person-years. The SIR for all cancers was 3.53. The SIR of follow-up period ≥ 10 years was 3.56; 5-10 years, 3.14; and 1-5 years, 3.06. The cancer SIRs of head and neck (15.83), stomach (3.30), lung and mediastinum (2.10), kidney (2.24) and leukemia (2.72), were significantly increased. Multivariate analysis showed that age ≥ 60 years (hazard ratio [HR] 0.74), being male (HR 1.46) and liver cirrhosis (HR 1.46) were independent factors. According to the treatments, major surgery (HR 1.24) increased the risk, but chemotherapy was nearly significant.
conclusionsPatients with esophageal cancer were at increased risk of developing metachronous SPMs. The SIR remained high in follow-up > 10 years, so that close monitoring may be needed for early detection of SPM among these esophageal cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.